10% of women around the world experience polycystic ovary syndrome (PCOS): an endocrine disorder that is also the top cause of infertility in women. May is addressing PCOS through its Ovarian Rebalancing™ treatment: a one-time ovarian cell ablation that aims to rebalance the ovaries, restore ovulation, and help women experiencing infertility.
CEO: Anne Morrissey
Headquarters: Menlo Park, CA
Year Founded: 2017
Year Avestria First Invested: 2024
Looking for a job opportunity at May Health? Click here.
May 13, 2024: May Health closed a $25 million Series B fundraising round. The funds will be used to support the company’s Ovarian Rebalancing™ therapy, specifically through its pivotal REBALANCE Study, and to evaluate the device’s potential to address infertility due to polycystic ovarian syndrome. The round was co-led by Bpifrance and Trill Impact and included participation from founding investor Sofinnova Partners, Kidron Capital Assets LP, and Avestria.
June 26, 2023: May Health announced the results of its safety and efficacy studies for its Ovarian Rebalancing treatment. Out of the 23 participants who received Ovarian Rebalancing and completed six months of follow-up, May Health saw a pregnancy rate of 35%, a spontaneous ovulation rate of 44%, a successful ablation rate of 100%, and no serious adverse side effects.
December 20, 2022: May Health completed the treatment for the first five patients enrolled in its Ovarian Rebalancing safety and efficacy study. The company has currently enrolled 23 patients across the United States and Europe in these feasibility studies.
September 9, 2022: May Health has solidified its veteran leadership team with the appointment of Anne Morrissey as Chief Executive Officer and Dr. Robert Auerbach, OBGYN, as chairman of the board. Both are experienced women’s healthcare executives and will help the company investigate its Ovarian Rebalancing™ technology. The company also announced its name change: from AblaCare to May Health,